NeuroVista's implantable device successfully and correctly predicted epilepsy seizures in some adults for whom drugs haven't worked, a new proof-of-concept study found.
NeuroPace is on the path to FDA approval for its anti-epilepsy neurostimulation device, winning unanimous backing from the agency's neurological devices panel.
A spinout of the Dutch conglomerate Royal Philips Electronics nabbed nearly $10 million in new venture funding to back ongoing development of a deep-brain stimulation implant to treat Parkinson's disease.
Lyrica, Pfizer's once-daily controlled-release formulation of pregabalin, missed the main endpoint of the first of three Phase III studies, according to a press release from the company.
The study, which tested the formulation as a once-a-day therapy, missed its main goal of changing seizure frequency compared with placebo.
Cyberonics ($CYBX) bucked sluggish sales trends elsewhere in the medical device industry and reported strong financial results for its fiscal 2013 second quarter. Investors reacted well to the news, driving the stock up more than 7% in late morning trading to $50 per share.
Keppra (levetiracetam) gained approval 13 years ago as a treatment for epilepsy. But just as many drugs end up having unexpected uses in other indications, Keppra could also help treat some patients suffering from Alzheimer's disease, researchers from the Gladstone Institutes in San Francisco believe.
A genetic biomarker for the very rare and severe form of paralysis in children--alternating hemiplegia of childhood--could help speed up correct diagnosis, prevent misdiagnosis and inappropriate treatment, and may even lead to new therapeutics for this currently incurable disability. The mutated gene was found by a team including researchers from Duke University Medical Center.
Shares of Supernus Pharmaceuticals rocketed up more than 100% yesterday as word spread that the FDA had provided a tentative approval for its extended-release version of the generic epilepsy drug Topamax.
Supernus Pharmaceuticals has finally dusted off the paperwork and suggested a $12 to $14 price range on some 5.8 million shares.